Blueprint Medicines Corporation (NASDAQ:BPMC) Holdings Lowered by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 2.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 135,909 shares of the biotechnology company's stock after selling 3,834 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.21% of Blueprint Medicines worth $12,029,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth approximately $65,000. Thematics Asset Management purchased a new stake in Blueprint Medicines during the fourth quarter valued at about $72,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after buying an additional 375 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Blueprint Medicines during the fourth quarter valued at about $106,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Blueprint Medicines during the fourth quarter valued at about $116,000.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Percy H. Carter sold 1,051 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $128.25, for a total value of $134,790.75. Following the transaction, the insider directly owned 53,155 shares in the company, valued at $6,817,128.75. The trade was a 1.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the completion of the sale, the insider directly owned 16,944 shares in the company, valued at $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 13,351 shares of company stock worth $1,384,244. 4.21% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BPMC shares. Needham & Company LLC lowered shares of Blueprint Medicines from a "buy" rating to a "hold" rating and set a $130.00 target price for the company. in a report on Monday, June 2nd. UBS Group boosted their price objective on shares of Blueprint Medicines from $88.00 to $129.00 and gave the company a "neutral" rating in a research report on Thursday, June 5th. Stephens downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $150.00 to $135.00 in a report on Tuesday, June 3rd. HC Wainwright reiterated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Blueprint Medicines to a "hold" rating in a research note on Friday. Eighteen research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of "Hold" and an average price target of $128.25.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC remained flat at $129.46 during midday trading on Friday. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.80 and a quick ratio of 2.75. The firm's 50-day moving average is $120.01 and its two-hundred day moving average is $103.36. Blueprint Medicines Corporation has a one year low of $73.04 and a one year high of $129.65. The stock has a market cap of $8.36 billion, a P/E ratio of -52.41 and a beta of 0.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The firm had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. Blueprint Medicines's revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $1.40 earnings per share. On average, research analysts predict that Blueprint Medicines Corporation will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.